MiR-199a regulates cell proliferation and survival by targeting FZD7

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Song, Jiugang ^a,b   Gao, Liucun ^b,c   Yang, Guang ^a   Tang, Shanhong ^b,d   Xie, Huahong ^b   Wang, Yongji ^a   Wang, Jingbo ^b   Zhang, Yanping ^e   Jin, Jiang ^b   Gou, Yawen ^b   Yang, Zhiping ^b   Chen, Zheng ^b   Wu, Kaichun ^b   Liu, Jie ^f   Fan, Daiming ^b  

^a 309TH HOSPITAL OF PLA   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^d CHENGDU MILITARY GENERAL HOSPITAL   (China)

^e Department ofAuxiliary Diagnosis   (China)

^f FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIN D1; FRIZZLED PROTEIN; FRIZZLED TYPE 7 RECEPTOR; MICRORNA; MICRORNA 199A; MYC PROTEIN; UNCLASSIFIED DRUG; FZD7 PROTEIN, HUMAN; MIRN199 MICRORNA, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DISEASE MARKER; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; TUMOR VOLUME; UPREGULATION; GENE EXPRESSION REGULATION; GENETICS; HEPG2 CELL LINE; KAPLAN MEIER METHOD; LIVER TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; RNA INTERFERENCE;

BASE SEQUENCE; BINDING SITES; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; FRIZZLED RECEPTORS; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; RNA INTERFERENCE;

EID: 84907980051     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110074     Document Type: Article

References (51)

1. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45: 529-538.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
4. Schwartz M, Roayaie S, Konstadoulakis M (2007) Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol 4: 424-432.
5. Jemal A, Center MM, DeSantis C, Ward EM (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19: 1893-1907.
6. Sanyal AJ, Yoon SK, Lencioni R (2010) The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 15 Suppl 4: 14-22.
7. Aravalli RN, Steer CJ, Cressman EN (2008) Molecular mechanisms of hepatocellular carcinoma. Hepatology 48: 2047-2063.
8. Huang S, He X (2011) The role of microRNAs in liver cancer progression. Br J Cancer 104: 235-240.
9. Bushati N, Cohen SM (2007) microRNA functions. Annu Rev Cell Dev Biol 23: 175-205.
10. Kent OA, Mendell JT (2006) A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 25: 6188-6196.
11. Negrini M, Gramantieri L, Sabbioni S, Croce CM (2011) microRNA involvement in hepatocellular carcinoma. Anticancer Agents Med Chem 11: 500-521.
12. Braconi C, Henry JC, Kogure T, Schmittgen T, Patel T (2011) The role of microRNAs in human liver cancers. Semin Oncol 38: 752-763.
13. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103: 2257-2261.
14. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, et al. (2007) MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133: 647-658.
15. Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, et al. (2008) Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 14: 419-427.
16. Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, et al. (2008) MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 47: 1955-1963.
17. Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, et al. (2009) MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 49: 1571-1582.
18. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, et al. (2006) Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25: 2537-2545.
19. Hou J, Lin L, Zhou W, Wang Z, Ding G, et al. (2011) Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 19: 232-243.
20. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
21. Gullberg D, Liang S, He L, Zhao X, Miao Y, et al. (2011) MicroRNA Let-7f Inhibits Tumor Invasion and Metastasis by Targeting MYH9 in Human Gastric Cancer. PLoS One 6: e18409.
22. Song J, Xie H, Lian Z, Yang G, Du R, et al. (2006) Enhanced cell survival of gastric cancer cells by a novel gene URG4. Neoplasia 8: 995-1002.
23. Kim M, Lee HC, Tsedensodnom O, Hartley R, Lim YS, et al. (2008) Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. J Hepatol 48: 780-791.
24. Merle P, Kim M, Herrmann M, Gupte A, Lefranc¸ois L, et al. (2005) Oncogenic role of the frizzled-7/β-catenin pathway in hepatocellular carcinoma. Journal of Hepatology 43: 854-862.
25. Yates LA, Norbury CJ, Gilbert RJ (2013) The long and short of microRNA. Cell 153: 516-519.
26. Nelson KM and Weiss GJ (2008) MicroRNAs and cancer: past, present, and potential future. Mol Cancer Ther 7: 3655-3660.
27. Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, et al. (2007) Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 67: 6092-6099.
28. Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, et al. (2008) Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 47: 897-907.
29. Ji J, Shi J, Budhu A, Yu Z, Forgues M, et al. (2009) MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 361: 1437-1447.
30. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, et al. (2006) A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 126: 1203-1217.
31. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, et al. (2008) MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 14: 2690-2695.
32. Tsukigi M, Bilim V, Yuuki K, Ugolkov A, Naito S, et al. (2012) Re-expression of miR-199a suppresses renal cancer cell proliferation and survival by targeting GSK-3beta. Cancer Lett 315: 189-197.
33. Su SF, Chang YW, Andreu-Vieyra C, Fang JY, Yang Z, et al. (2013) miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer. Oncogene 32: 4694-4701.
34. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, et al. (2007) MicroRNA expression profiling in prostate cancer. Cancer Res 67: 6130-6135.
35. Yu T, Wang XY, Gong RG, Li A, Yang S, et al. (2009) The expression profile of microRNAs in a model of 7,12-dimethyl-benz[a]anthrance-induced oral carcinogenesis in Syrian hamster. J Exp Clin Cancer Res 28: 64.
36. Lee JW, Choi CH, Choi JJ, Park YA, Kim SJ, et al. (2008) Altered MicroRNA expression in cervical carcinomas. Clin Cancer Res 14: 2535-2542.
37. Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, et al. (2010) Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol 11: 136-146.
38. He XJ, Ma YY, Yu S, Jiang XT, Lu YD, et al. (2014) Up-regulated miR-199a-5p in gastric cancer functions as an oncogene and targets klotho. BMC Cancer 14: 218.
39. Mascaux C, Laes JF, Anthoine G, Haller A, Ninane V, et al. (2009) Evolution of microRNA expression during human bronchial squamous carcinogenesis. Eur Respir J 33: 352-359.
40. Ueno K, Hazama S, Mitomori S, Nishioka M, Suehiro Y, et al. (2009) Down-regulation of frizzled-7 expression decreases survival, invasion and metastatic capabilities of colon cancer cells. Br J Cancer 101: 1374-1381.
41. Tanaka S, Akiyoshi T, Mori M, Wands JR, Sugimachi K (1998) A novel frizzled gene identified in human esophageal carcinoma mediates APC/beta-catenin signals. Proc Natl Acad Sci U S A 95: 10164-10169.
42. Yang L, Wu X, Wang Y, Zhang K, Wu J, et al. (2011) FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene 30: 4437-4446.
43. Sagara N, Toda G, Hirai M, Terada M, Katoh M (1998) Molecular cloning, differential expression, and chromosomal localization of human frizzled-1, frizzled-2, and frizzled-7. Biochem Biophys Res Commun 252: 117-122.
44. Li CM, Guo M, Borczuk A, Powell CA, Wei M, et al. (2002) Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. Am J Pathol 160: 2181-2190.
45. Kirikoshi H, Sekihara H, Katoh M (2001) Up-regulation of Frizzled-7 (FZD7) in human gastric cancer. Int J Oncol 19: 111-115.
46. Melchior K, Weiss J, Zaehres H, Kim YM, Lutzko C, et al. (2008) The WNT receptor FZD7 contributes to self-renewal signaling of human embryonic stem cells. Biol Chem 389: 897-903.
47. Ueno K, Hiura M, Suehiro Y, Hazama S, Hirata H, et al. (2008) Frizzled-7 as a potential therapeutic target in colorectal cancer. Neoplasia 10: 697-705.
48. Nambotin SB, Lefrancois L, Sainsily X, Berthillon P, Kim M, et al. (2011) Pharmacological inhibition of Frizzled-7 displays anti-tumor properties in hepatocellular carcinoma. J Hepatol 54: 288-299.
49. Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, et al. (2010) Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol 176: 2911-2920.
50. Pode-Shakked N, Harari-Steinberg O, Haberman-Ziv Y, Rom-Gross E, Bahar S, et al. (2011) Resistance or sensitivity of Wilms' tumor to anti-FZD7 antibody highlights the Wnt pathway as a possible therapeutic target. Oncogene 30: 1664-1680.
51. Fujii N, You L, Xu Z, Uematsu K, Shan J, et al. (2007) An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth. Cancer Res 67: 573-579.